
The marketing authorisation for Sanofi’s dengue vaccine Dengvaxia has been revoked in the Philippines after the country’s Food and Drug …

A novel and potentially “game-changing” oral therapy for the treatment of osteoarthritis (OA) has received a £675,000 cash injection from …

On 14 January, the European Commission issued marketing approval for Flucelvax Tetra, the first cell-based, quadrivalent influenza vaccine. Pharmafocus spoke …

Japanese pharma firm Astellas has lifted the curtain on new data for its androgen receptor signalling inhibitor Xtandi (enzalutamide), when …

New interim data for the combination of Pfizer’s Bavencio (avelumab) and Merck KGaA’s Inlyta (axitinib) have been released, showing that …

Boehringer Ingelheim and Eli Lilly’s Trajenta (linagliptin) met its primary endpoint in a recent trial, it has emerged, proving itself …

NICE has announced its decision to authorise the use of Roche’s Perjeta (pertuzumab) on the NHS for the treatment of …

Researchers at the University of Leicester alongside colleagues in Vancouver, Canada, have revealed data that supports the efficacy of an …

Takeda’s Adcetris (brentuximab vedotin) has seen its marketing authorisation expanded by the European Commission to include the treatment of previously …

The FDA has taken the decision to authorise the use of Novartis’ Egaten (triclabendazole) in patients older than six years …

Novartis has arranged to sell the remainder of its rights to its skin and lung cancer drug Proleukin (aldesleukin, recombinant …

In a bid to bolster its footing in providing surgical treatments, Johnson & Johnson has announced it will acquire robotics …

Bristol-Myers Squibb’s Sprycel (dasatinib) has secured an expanded indication in Europe, the company said, with the European Commission greenlighting the …

In a rare and welcomed development in the treatment of major depressive disorder (MDD), Janssen has announced that its esketamine …

New data has been revealed on the efficacy of MSD’s Keytruda (pembrolizumab) in combination with Pfizer’s Inlyta (axitinib), showing it …